Inactive Instrument

Other languages Akers Biosciences Inc Nasdaq

Equities

US00973E1029

Other languages

Unlock all the news: Be the first to know and act before the market!

MyMD Pharmaceuticals, Inc. Announces Management Changes	06-17
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15
MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer	04-18
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	04-09
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	04-09
Top Premarket Gainers	04-09
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01
MyMD Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Listing Requirement	03-05
MyMD Pharmaceuticals to Implement 1-for-30 Reverse Stock Split	02-13
MyMD Pharmaceuticals, Inc. Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis	12-06
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14
Mymd Pharmaceuticals, Inc. Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain	23-10-19
MyMD Pharmaceuticals, Inc. to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023	23-10-04
Insider Buy: Mymd Pharmaceuticals	23-08-24
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
MyMD Pharmaceuticals Says Its Investigational New Drug Application for Rheumatoid Arthritis Treatment Gets FDA Acceptance	23-08-14
FDA Accepts MyMD Pharmaceuticals, Inc. Investigational New Drug Application for Phase 2 Study of Oral Tnf-A Inhibitor Mymd-1®? in Rheumatoid Arthritis	23-08-14
MyMD Pharmaceuticals' MYMD-1 Study Shows Positive Results for Age-Related inflammation Drug; Shares Rise	23-07-31
Mymd Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral Tnf-A Inhibitor Mymd-1® in Sarcopenia/Age-Related Frailty	23-07-31
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Akers Biosciences Inc Nasdaq

Equities

US00973E1029

Other languages

Filters